It has been established from multiple randomised, placebo-controlled trials that angiotensin-
converting enzyme inhibitors reduce the risk of death and major non-fatal cardiovascular …

There is strong evidence from controlled clinical trials that in the setting of acute myocardial
infarction complicated by heart failure or isolated left ventricular dysfunction, angiotensin …

Background Survivors of acute myocardial infarction (MI) complicated by heart failure and/or
resulting in left ventricular dysfunction are at heightened risk for subsequent death and …

A number of therapies are beneficial in the management of patients with acute myocardial
infarction (MI), including revascularization with either percutaneous coronary intervention or …

Angiotensin-converting enzyme inhibitors (ACE-Is) are an evidence-based treatment for
patients who after myocardial infarction (MI) present with either heart failure (HF) or left …

Objectives: We attempted to compare the effect of an angiotensin-converting enzyme (ACE)
inhibitor and angiotensin receptor blocker (ARB) on atherosclerotic events. Background …

Treatment of acute myocardial infarction (MI) has been advanced considerably in the past
20 years with the advent of acute reperfusion strategies such as thrombolytic therapy or …

Angiotensin‐converting enzyme inhibitor therapy has been shown to be effective in treating
patients across the spectrum of cardiac disease. Utility has been demonstrated for both …

Concern has been raised about combining β blockers with angiotensin-receptor blockers in
patients with heart failure. The VALsartan In Acute myocardial infarction (VALIANT) trial …

Patients with acute myocardial infarction and evidence of heart failure or left ventricular
dysfunction during the acute phase have an excessive mortality risk. Therapy with …